Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Stock in Sarepta Therapeutics Inc. (Nasdaq: SRPT) fell 8 percent on Monday, and some speculate it’s because of doubts about whether levels of dystrophin in the body can be used to measure the progression of Duchenne’s muscular dystrophy (DMD). The Cambridge, Mass. biotech got a boost Friday when a competitor in the Duchenne’s muscular dystrophy market, Prosensa, released disappointing data from its Phase 2 trial of a DMD drug, drisapersen. Sarepta is developing eteplirsen for DMD, which currently has no approved treatment.
Help employers find you! Check out all the jobs and post your resume.
